Calidi Biotherapeutics, Inc.
CLDWW- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001855485
No open-market purchases or sales by Calidi Biotherapeutics, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Other share classesCLDI
13F holders, Q1 2024
Institutional positions in Calidi Biotherapeutics, Inc. as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 17
- 0 vs. Q4 2023
- Shares held
- 5.63M
- +98.3K (+1.8%) vs. Q4 2023
- Total value
- $385.1K
- +$6.44K (+1.7%) vs. Q4 2023
- New holders
- 3
- 0 more added
- Sold out
- 3
- 1 more reduced
1 institution that held it in Q4 2023 haven't filed for Q1 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CLDWW on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 1 | $1.01K |
| Q3 2024 | 16 | $99.4K |
| Q2 2024 | 17 | $281.5K |
| Q1 2024 | 17 | $385.1K |
| Q4 2023 | 18 | $384.0K |
| Q3 2023 | 22 | $1.64M |
| Q2 2023 | 22 | $866.3K |
| Q1 2023 | 24 | $366.1K |
| Q4 2022 | 25 | $350.0K |
| Q3 2022 | 27 | $479.9K |
| Q2 2022 | 28 | $767.0K |
| Q1 2022 | 29 | $2.83M |
| Q4 2021 | 23 | $3.01M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding Calidi Biotherapeutics, Inc.; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Polar Asset Management Partners Inc. | 2,165,086 | $119.1K | 0.00% | 00.0% | Unchanged |
| Highbridge Capital Management LLC | – | $84.7K | 0.00% | – | – |
| Finepoint Capital LP | 655,200 | $34.1K | 0.01% | 00.0% | Unchanged |
| 683 Capital Management, LLC | 600,000 | $31.2K | 0.00% | 00.0% | Unchanged |
| Aristeia Capital LLC | 494,400 | $27.2K | 0.00% | 00.0% | Unchanged |
| Nomura Holdings Inc | 467,818 | $24.3K | 0.00% | 00.0% | Unchanged |
| Shaolin Capital Management LLC | 450,000 | $23.4K | 0.00% | 00.0% | Unchanged |
| Arena Investors LP | 333,333 | $17.3K | 0.70% | 00.0% | Unchanged |
| Cowen and Company, LLC | 172,136 | $8.95K | 0.00% | −100−0.1% | Reduced |
| EHP Funds Inc. | 107,964 | $5.61K | 0.00% | 00.0% | Unchanged |
| Exos Asset Management LLC | 105,000 | $5.46K | 0.00% | +105,000 | New |
| Walleye Capital LLC | 36,469 | $1.90K | 0.00% | 00.0% | Unchanged |
| Walleye Trading LLC | 20,052 | $1.04K | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 15,873 | $825 | 0.00% | +15,873 | New |
| Clear Street LLC | 1,746 | $91 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 133 | $7 | 0.00% | +133 | New |
| The PNC Financial Services Group, Inc. | 50 | $3 | 0.00% | 00.0% | Unchanged |
| Wolverine Asset Management LLC | 0 | $0 | 0.00% | −5,229−100.0% | Sold out |
| Sea Otter Advisors LLC | 0 | $0 | 0.00% | −4,871−100.0% | Sold out |
| Bank of Montreal | 0 | $0 | 0.00% | −12,500−100.0% | Sold out |
| Exos TFP Holdings LLC | – | – | – | – | Not filed |